Chinanews.com, June 6 -- On June 10, the National Health Insurance Administration announced the "6 National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue Adjustment Work Plan" and related documents for public comments.
According to the Work Plan, taking into account the functional positioning of basic medical insurance and work-related injury insurance, the clinical demand for drugs, and the affordability of funds, the scope of adjustment of the drug list in 2023 is as follows:
Off-the-list Western medicine and proprietary Chinese medicine
Drugs that comply with Articles 2023 and <> of the Interim Measures for the Administration of Drugs for Basic Medical Insurance and have any of the following circumstances may be declared to participate in the adjustment of the drug list in <>.
1. From January 2018, 1 to June 1, 2023 (inclusive, the same below), new generic drugs approved for marketing by the national drug administration. New crown treatment drugs that meet this condition can be declared according to the procedure.
2. Drugs that have undergone major changes in indications or functional indications approved by the national drug administration from January 2018, 1 to June 1, 2023, and have obtained drug approval certificates for this change.
3. Drugs included in the National Essential Medicines List (2018 Edition).
4. Drugs included in the list of encouraged generic drugs or the list of children's drugs that are encouraged to be developed and declared, and which have been approved for marketing by the national drug administration before June 2023, 6.
5. Before June 2023, 6, rare disease treatment drugs approved by the national drug administration.
Western medicine and Chinese proprietary medicine in the catalog
1. Negotiated drugs with an expiring agreement on December 2023, 12.
2. The agreement expires on December 2024, 12, and between January 31, 2018 and June 1, 1, with the approval of the national drug administration, the indications or functional indications undergo major changes, and the enterprise takes the initiative to declare the negotiated drug to adjust the medical insurance payment scope.
3. From January 2018, 1 to June 1, 2023, with the approval of the national drug administration, major changes in indications or functional indications have occurred, and enterprises have taken the initiative to declare drugs in the routine catalogue part of the adjustment of medical insurance payment coverage.
4. Drugs that comply with the provisions of Articles <> and <> of the Interim Measures for the Administration of Drugs by Basic Medical Insurance.
other
1. Include eligible Chinese medicine pieces in the scope of adjustment according to regulations.
2. Improve the examples of drug catalogs, standardize drug names and dosage forms, and appropriately adjust drug A and B categories, catalog classification structure, remarks, etc.
3. The identification of exclusive drugs is subject to June 2023, 6.
4. Non-exclusive drugs to be included in the drug catalogue shall be determined simultaneously by means of bidding and other methods.
The Work Plan also points out that the adjustment of the national drug list in 2023 is divided into five stages: preparation (May-June 2023), declaration (July-August 5), expert review (August-September 6), negotiation/bidding (September-November 2023), and announcement of results (November 7).
Members of the public can submit comments and suggestions by 2023:6 on Thursday, June 15, 17, and feedback can be submitted in writing or by email. The Rules for Negotiating Drug Renewal and the Rules for Non-Exclusive Bidding for Non-Exclusive Drugs will be solicited for comments separately.
Translation
Search
copy